Insight Molecular Diagnostics (IMDX) Q1 2026 earnings summary

Executive summary

• Submitted GraftAssureDx to the FDA in March 2026, targeting kidney transplants first, with productive regulatory engagement and first significant U.S. orders expected post-approval.

• Early international research-use kit sales in Switzerland and Southeast Asia, with initial reimbursement established in at least one market.

• Strategic partnership with Bio-Rad to co-develop and commercialize transplant test kits, with first RUO kit sales in May 2025.

• GALACTIC Registry Study interest increased to 34 U.S. transplant centers, with first clinical trial agreement signed and a goal of 50 centers.

• Expansion into heart transplant testing underway, leveraging organ-agnostic assay design and R&D for additional organ types.

Financial highlights

• Q1 2026 revenue was $32,000, all from laboratory services; Q2 2026 revenue projected at $250,000, mainly from laboratory services and minimal GraftAssureIQ sales.

• Net loss for Q1 2026 was $4.3 million, improved from $6.7 million in Q1 2025, mainly due to a $5.9 million gain from contingent consideration.

• Cash, cash equivalents, and restricted cash at March 31, 2026, totaled $29.4 million, bolstered by a $26 million direct offering in February 2026.

• Q2 cash burn expected to exceed $9 million due to bonuses and FDA submission expenses, anticipated to decrease to ~$6 million per quarter in the second half of the year.

• Medicare reimburses GraftAssureCore at $2,753 per result.

Outlook and guidance

• First U.S. orders for GraftAssure expected later in 2026, with significant revenue growth anticipated from commercialization of transplant kits and expansion into additional organ types.

• Cash burn projected to decline in the second half of 2026 as FDA-related expenses subside and revenue ramps.

• Long-term target gross margin of 70% or higher, though initial contracts may be lower due to leader pricing and a 10% revenue share with former IP holders.

• EU IVDR submission planned for later in 2026, with approval expected in 6–12 months post-submission; CE Mark in the U.K. anticipated.

• Management expects continued operating losses and negative cash flows as investment in transplant and kitted product development continues.